Skip to main content
. 2007 Dec 22;35(5):1008–1018. doi: 10.1007/s00259-007-0658-0

Fig. 3.

Fig. 3

The binding of [18F]FBEM-ZHER2:342-Affibody molecules to cells with different levels of HER2 expression [cell line versus normalized cell-associated radioactivity (%) and the effect of pre-incubation with either Affibody molecules or trastuzumab on the binding, n = 3]. The standard errors were in the range 0.1 to 3.1%